{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:25:51Z","timestamp":1790040351260,"version":"4.0.1"},"reference-count":137,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Several immune checkpoint molecules and immune targets in leukemic cells have been investigated. Recent studies have suggested the potential clinical benefits of immuno-oncology (IO) therapy against acute myeloid leukemia (AML), especially targeting CD33, CD123, and CLL-1, as well as immune checkpoint inhibitors (e.g., anti-PD (programmed cell death)-1 and anti-CTLA4 (cytotoxic T-lymphocyte-associated protein 4) antibodies) with or without conventional chemotherapy. Early-phase clinical trials of chimeric antigen receptor (CAR)-T or natural killer (NK) cells for relapsed\/refractory AML showed complete remission (CR) or marked reduction of marrow blasts in a few enrolled patients. Bi-\/tri-specific antibodies (e.g., bispecific T-cell engager (BiTE) and dual-affinity retargeting (DART)) exhibited 11\u201367% CR rates with 13\u201378% risk of cytokine-releasing syndrome (CRS). Conventional chemotherapy in combination with anti-PD-1\/anti-CTLA4 antibody for relapsed\/refractory AML showed 10\u201336% CR rates with 7\u201324 month-long median survival. The current advantages of IO therapy in the field of AML are summarized herein. However, although cancer vaccination should be included in the concept of IO therapy, it is not mentioned in this review because of the paucity of relevant evidence.<\/jats:p>","DOI":"10.3390\/ijms22041944","type":"journal-article","created":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T22:13:38Z","timestamp":1613513618000},"page":"1944","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Emerging Immunotherapy for Acute Myeloid Leukemia"],"prefix":"10.3390","volume":"22","author":[{"given":"Rikako","family":"Tabata","sequence":"first","affiliation":[{"name":"Department of Hematology, National Cancer Center Hospital East, Kashiwa 277-8577, Japan"},{"name":"Department of Hematology, Kameda Medical Center, Kamogawa 296-8602, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5725-7187","authenticated-orcid":false,"given":"SungGi","family":"Chi","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Cancer Center Hospital East, Kashiwa 277-8577, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4908-1636","authenticated-orcid":false,"given":"Junichiro","family":"Yuda","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Cancer Center Hospital East, Kashiwa 277-8577, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Minami","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Cancer Center Hospital East, Kashiwa 277-8577, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/14737140.2016.1211936","article-title":"Ipilimumab in melanoma","volume":"16","author":"Specenier","year":"2016","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed\/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5192","DOI":"10.1200\/JCO.2007.15.9764","article-title":"Long-Term Disease-Free Survival After Gemtuzumab, Intermediate-Dose Cytarabine, and Mitoxantrone in Patients With CD33+Primary Resistant or Relapsed Acute Myeloid Leukemia","volume":"26","author":"Chevallier","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: A meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1749-6632.2010.05919.x","article-title":"The role of the PD-1 pathway in autoimmunity and peripheral tolerance","volume":"1217","author":"Fife","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.gene.2017.09.050","article-title":"PD-1 pathway and its clinical application: A 20 year journey after discovery of the complete human PD-1 gene","volume":"638","author":"Berger","year":"2018","journal-title":"Gene"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1084\/jem.174.3.561","article-title":"CTLA-4 is a second receptor for the B cell activation antigen B7","volume":"174","author":"Linsley","year":"1991","journal-title":"J. Exp. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev.immunol.24.021605.090535","article-title":"A MOLECULAR PERSPECTIVE OF CTLA-4 FUNCTION","volume":"24","author":"Teft","year":"2006","journal-title":"Annu. Rev. Immunol."},{"key":"ref_14","first-page":"2146","article-title":"Negative effect of CTLA-4 on induction of T-cell immunity in vivo to B7-1+, but not B7-2+, murine myelogenous leukemia","volume":"99","author":"LaBelle","year":"2002","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"622","DOI":"10.4161\/cbt.7.5.5689","article-title":"Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia","volume":"7","author":"Chen","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/leu.2016.328","article-title":"PD-L1 (CD274) promoter methylation predicts survival in patients with acute myeloid leukemia","volume":"31","author":"Goltz","year":"2017","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Goswami, M., Oetjen, K., Mul\u00e9, B.M.P., Sheela, M.S., Wong, H.Y., Liu, Q., Calvo, K.R., Lai, C.E., and Hourigan, C.S. (2016). Increased Frequencies of PD-1+ CD8+ Marrow-Infiltrating Lymphocytes Associated with Highly Clonal T-Lymphocyte Expansions in Relapsed and Refractory AML Patients but Not Healthy Adults. Blood, 128.","DOI":"10.1182\/blood.V128.22.1644.1644"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Daver, N., Basu, S., Garcia-Manero, G., Cortes, J.E., Ravandi, F., Ning, J., Xiao, L., Juliana, L., Kornblau, S.M., and Konopleva, M. (2016). Defining the Immune Checkpoint Landscape in Patients (pts) with Acute Myeloid Leukemia (AML). Blood, 128.","DOI":"10.1182\/blood.V128.22.2900.2900"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"463","DOI":"10.21147\/j.issn.1000-9604.2017.05.11","article-title":"Higher PD-1 expression concurrent with exhausted CD8+ T cells in patients with de novo acute myeloid leukemia","volume":"29","author":"Tan","year":"2017","journal-title":"Chin. J. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Schnorfeil, F.M., Lichtenegger, F.S., Emmerig, K., Schlueter, M., Neitz, J.S., Draenert, R., Hiddemann, W., and Subklewe, M. (2015). T cells are functionally not impaired in AML: Increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment. J. Hematol. Oncol., 8.","DOI":"10.1186\/s13045-015-0189-2"},{"key":"ref_22","first-page":"536","article-title":"Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease","volume":"415","author":"Monney","year":"2002","journal-title":"Nat. Cell Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/ni987","article-title":"Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance","volume":"4","author":"Tian","year":"2003","journal-title":"Nat Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Tomkowicz, B., Walsh, E.R., Cotty, A., Verona, R., Sabins, N., Kaplan, F., Santulli-Marotto, S., Chin, C.-N., Mooney, J.L., and Lingham, R.B. (2015). TIM-3 Suppresses Anti-CD3\/CD28-Induced TCR Activation and IL-2 Expression through the NFAT Signaling Pathway. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0140694"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1002\/eji.201344392","article-title":"Enhanced suppressor function of TIM-3+FoxP3+regulatory T cells","volume":"44","author":"Gautron","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cellimm.2008.01.006","article-title":"The Tim-3 ligand galectin-9 negatively regulates CD8+ alloreactive T cell and prolongs survival of skin graft","volume":"250","author":"Wang","year":"2007","journal-title":"Cell. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"10650","DOI":"10.1073\/pnas.1017954108","article-title":"Galectin-9 binding to cell surface protein disulfide isomerase regulates the redox environment to enhance T-cell migration and HIV entry","volume":"108","author":"Bi","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1002\/eji.201343335","article-title":"Proinflammatory stimuli induce galectin-9 in human mesenchymal stromal cells to suppress T-cell proliferation","volume":"43","author":"Gieseke","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1128\/JVI.01085-12","article-title":"Galectin-9 Functionally Impairs Natural Killer Cells in Humans and Mice","volume":"87","author":"Mcmahan","year":"2013","journal-title":"J. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.4049\/jimmunol.0903059","article-title":"T Cell\/Transmembrane, Ig, and Mucin-3 Allelic Variants Differentially Recognize Phosphatidylserine and Mediate Phagocytosis of Apoptotic Cells","volume":"184","author":"DeKruyff","year":"2010","journal-title":"J. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/ni.2376","article-title":"Tumor-infiltrating DCs suppress nucleic acid\u2013mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1","volume":"13","author":"Chiba","year":"2012","journal-title":"Nat. Immunol."},{"key":"ref_32","first-page":"386","article-title":"CEACAM1 regulates TIM-3-mediated tolerance and exhaustion","volume":"517","author":"Huang","year":"2015","journal-title":"Nat. Cell Biol."},{"key":"ref_33","first-page":"6880","article-title":"Tim-3 is highly expressed in T cells in acute myeloid leukemia and associated with clinicopathological prognostic stratification","volume":"7","author":"Li","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Kong, Y., Zhang, J., Claxton, D.F., Ehmann, W.C., Rybka, W.B., Zhu, L., Zeng, H., Schell, T.D., and Zheng, H. (2015). PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. Blood Cancer J., 5.","DOI":"10.1038\/bcj.2015.58"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Zhou, Q., Munger, M.E., Veenstra, R.G., Weigel, B.J., Hirashima, M., Munn, D.H., Murphy, W.J., Azuma, M., Anderson, A.C., and Kuchroo, V.K. (2011). Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood J. Am. Soc. Hematol., 117.","DOI":"10.1182\/blood-2010-10-310425"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Han, G., Chen, G., Shen, B., and Li, Y. (2013). Tim-3: An Activation Marker and Activation Limiter of Innate Immune Cells. Front. Immunol., 4.","DOI":"10.3389\/fimmu.2013.00449"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2011-06-360321","article-title":"Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9","volume":"119","author":"Gleason","year":"2012","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-015-0134-4","article-title":"TIM-3\/Gal-9 interaction induces IFN\u03b3-dependent IDO1 expression in acute myeloid leukemia blast cells","volume":"8","author":"Folgiero","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ebiom.2017.07.018","article-title":"The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia Cells","volume":"22","author":"Silva","year":"2017","journal-title":"EBioMedicine"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood.2019002779","article-title":"Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia","volume":"135","author":"He","year":"2020","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1084\/jem.176.2.327","article-title":"Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens","volume":"176","author":"Baixeras","year":"1992","journal-title":"J. Exp. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.4049\/jimmunol.0800185","article-title":"LAG-3 Regulates Plasmacytoid Dendritic Cell Homeostasis","volume":"182","author":"Workman","year":"2009","journal-title":"J. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"6545","DOI":"10.4049\/jimmunol.0903879","article-title":"LAG-3 Expression Defines a Subset of CD4+CD25highFoxp3+ Regulatory T Cells That Are Expanded at Tumor Sites","volume":"184","author":"Camisaschi","year":"2010","journal-title":"J. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1084\/jem.171.5.1393","article-title":"LAG-3, a novel lymphocyte activation gene closely related to CD4","volume":"171","author":"Triebel","year":"1990","journal-title":"J. Exp. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1002\/eji.1830241246","article-title":"Lymphocyte-activation gene 3\/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes","volume":"24","author":"Huard","year":"1994","journal-title":"Eur. J. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/eji.1830260533","article-title":"T cell major histocompatibility complex class II molecules down-regulate CD4+ T cell clone responses following LAG-3 binding","volume":"26","author":"Huard","year":"1996","journal-title":"Eur. J. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1084\/jem.20100466","article-title":"PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice","volume":"208","author":"Okazaki","year":"2011","journal-title":"J. Exp. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/cncr.31896","article-title":"The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia","volume":"125","author":"Williams","year":"2019","journal-title":"Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1182\/blood-2017-06-792267","article-title":"Dual PD1\/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia","volume":"131","author":"Wierz","year":"2018","journal-title":"Blood"},{"key":"ref_51","unstructured":"Bristol-Myers Squibb (2020, June 21). A Phase 1\/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 (BMS-986016) in Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Relapsed or Refractory B-Cell Malignancies. clinicaltrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02061761."},{"key":"ref_52","unstructured":"Bristol-Myers Squibb (2020, June 21). A Phase I\/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors. clinicaltrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01968109."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.4049\/jimmunol.167.5.2547","article-title":"Bidirectional Negative Regulation of Human T and Dendritic Cells by CD47 and Its Cognate Receptor Signal-Regulator Protein-\u03b1: Down-Regulation of IL-12 Responsiveness and Inhibition of Dendritic Cell Activation","volume":"167","author":"Latour","year":"2001","journal-title":"J. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1084\/jem.193.7.855","article-title":"Cd47-Signal Regulatory Protein \u03b1 (Sirp\u03b1) Regulates Fc\u03b3 and Complement Receptor\u2013Mediated Phagocytosis","volume":"193","author":"Oldenborg","year":"2001","journal-title":"J. Exp. Med."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Piccio, L., Vermi, W., Boles, K.S., Fuchs, A., Strader, C.A., Facchetti, F., Cella, M., and Colonna, M. (2005). Adhesion of human T cells to antigen-presenting cells through SIRP\u24242-CD47 interaction costimulates T-cell proliferation. Blood, 105.","DOI":"10.1182\/blood-2004-07-2823"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","article-title":"CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis","volume":"138","author":"Jaiswal","year":"2009","journal-title":"Cell"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1158\/1078-0432.CCR-16-1700","article-title":"TTI-621 (SIRP\u03b1Fc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding","volume":"23","author":"Petrova","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin\u2019s Lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1111\/trf.15397","article-title":"The effects of monoclonal anti-CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia","volume":"59","author":"Brierley","year":"2019","journal-title":"Transfusion"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/bjh.15078","article-title":"Immune checkpoint molecules in acute myeloid leukaemia: Managing the double-edged sword","volume":"181","author":"Hobo","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"6420","DOI":"10.4049\/jimmunol.175.10.6420","article-title":"Functional Analysis of B and T Lymphocyte Attenuator Engagement on CD4+ and CD8+ T Cells","volume":"175","author":"Krieg","year":"2005","journal-title":"J. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1074-7613(00)00023-6","article-title":"Lymphoid\/Neuronal Cell Surface OX2 Glycoprotein Recognizes a Novel Receptor on Macrophages Implicated in the Control of Their Function","volume":"13","author":"Wright","year":"2000","journal-title":"Immunity"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2017.01.021","article-title":"Over-expression of CD200 predicts poor prognosis in MDS","volume":"56","author":"Chen","year":"2017","journal-title":"Leuk. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/mt.2011.88","article-title":"Active Immunotherapy Combined With Blockade of a Coinhibitory Pathway Achieves Regression of Large Tumor Masses in Cancer-prone Mice","volume":"19","author":"Lasaro","year":"2011","journal-title":"Mol. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/leu.2011.1","article-title":"CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia","volume":"25","author":"Coles","year":"2011","journal-title":"Leukemia"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.4049\/jimmunol.173.4.2500","article-title":"Murine B7-H3 is a negative regulator of T cells","volume":"173","author":"Prasad","year":"2004","journal-title":"J. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-15-2428","article-title":"Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy","volume":"22","author":"Picarda","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Lichtman, E., Du, H., Savoldo, B., Ferrone, S., Li, G., Su, L., and Dotti, G. (2018). Pre-Clinical Evaluation of B7-H3-Specific Chimeric Antigen Receptor T-Cells for the Treatment of Acute Myeloid Leukemia. Blood, 132.","DOI":"10.1182\/blood-2018-99-113468"},{"key":"ref_70","first-page":"1261","article-title":"Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies","volume":"86","author":"Carnicer","year":"2001","journal-title":"Haematologica"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Testa, U., Pelosi, E., and Frankel, A. (2014). CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomark. Res., 2.","DOI":"10.1186\/2050-7771-2-4"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1038\/bcj.2014.39","article-title":"Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia","volume":"4","author":"Ehninger","year":"2014","journal-title":"Blood Cancer J."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3324\/haematol.2011.047894","article-title":"High levels of CD34+CD38low\/\u2212CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: A Groupe Ouest-Est des Leuc\u00e9mies Aigu\u00ebs et Maladies du Sang (GOELAMS) study","volume":"96","author":"Vergez","year":"2011","journal-title":"Haematologica"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1158\/1078-0432.CCR-14-3186","article-title":"A Leukemia-Associated CD34\/CD123\/CD25\/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia","volume":"21","author":"Angelini","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/s41375-018-0279-6","article-title":"Histone deacetylase inhibitor targets CD123\/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia","volume":"33","author":"Yan","year":"2019","journal-title":"Leukemia"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/blood-2014-05-575704","article-title":"Targeting CD123 in acute myeloid leukemia using a T-cell\u2013directed dual-affinity retargeting platform","volume":"127","author":"Rettig","year":"2016","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/leu.2014.62","article-title":"Chimeric antigen receptors against CD33\/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo","volume":"28","author":"Pizzitola","year":"2014","journal-title":"Leukemia"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1038\/mt.2016.116","article-title":"CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia","volume":"24","author":"Bonifant","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Xie, L.H., Biondo, M., Busfield, S.J., Arruda, A., Yang, X., Vairo, G., and Minden, M.D. (2017). CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission. Blood Cancer J., 7.","DOI":"10.1038\/bcj.2017.52"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1158\/1078-0432.CCR-16-1904","article-title":"Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia","volume":"23","author":"Han","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/bloodadvances.2018017517","article-title":"A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells","volume":"2","author":"Kovtun","year":"2018","journal-title":"Blood Adv."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood-2005-03-1072","article-title":"Hematopoietic stem cells express multiple myeloid markers: Implications for the origin and targeted therapy of acute myeloid leukemia","volume":"106","author":"Taussig","year":"2005","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.3324\/haematol.2011.043786","article-title":"High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation","volume":"96","author":"Raponi","year":"2011","journal-title":"Haematologica"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/leu.2016.309","article-title":"Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia","volume":"31","author":"Khan","year":"2017","journal-title":"Leukemia"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1182\/blood-2016-01-689976","article-title":"The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia","volume":"127","author":"Olombel","year":"2016","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1182\/blood-2011-12-398370","article-title":"Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML","volume":"119","author":"Pollard","year":"2012","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1158\/1535-7163.MCT-13-0956","article-title":"Preclinical Characterization of AMG 330, a CD3\/CD33-Bispecific T-Cell\u2013Engaging Antibody with Potential for Treatment of Acute Myelogenous Leukemia","volume":"13","author":"Friedrich","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2018-05-849802","article-title":"Bifunctional PD-1 \u00d7 \u03b1CD3 \u00d7 \u03b1CD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia","volume":"132","author":"Herrmann","year":"2018","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.immuni.2013.12.015","article-title":"Clec12a Is an Inhibitory Receptor for Uric Acid Crystals that Regulates Inflammation in Response to Cell Death","volume":"40","author":"Neumann","year":"2014","journal-title":"Immunity"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1136\/annrheumdis-2014-206644","article-title":"MICL controls inflammation in rheumatoid arthritis","volume":"75","author":"Redelinghuys","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1182\/blood-2007-03-083048","article-title":"The novel AML stem cell\u2013associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells","volume":"110","author":"Kelder","year":"2007","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.4049\/jimmunol.1600011","article-title":"CLEC12A-Mediated Antigen Uptake and Cross-Presentation by Human Dendritic Cell Subsets Efficiently Boost Tumor-Reactive T Cell Responses","volume":"197","author":"Hutten","year":"2016","journal-title":"J. Immunol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1158\/1078-0432.CCR-18-0333","article-title":"An Anti\u2013CLL-1 Antibody\u2013Drug Conjugate for the Treatment of Acute Myeloid Leukemia","volume":"25","author":"Zheng","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1182\/bloodadvances.2018020107","article-title":"CLT030, a leukemic stem cell\u2013targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia","volume":"2","author":"Jiang","year":"2018","journal-title":"Blood Adv."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0726-5","article-title":"Targeting CLL-1 for acute myeloid leukemia therapy","volume":"12","author":"Ma","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3324\/haematol.2009.009811","article-title":"Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia","volume":"95","author":"Zhao","year":"2009","journal-title":"Haematologica"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1182\/blood-2016-08-735365","article-title":"An anti-CD3\/anti\u2013CLL-1 bispecific antibody for the treatment of acute myeloid leukemia","volume":"129","author":"Leong","year":"2017","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"9841","DOI":"10.1002\/anie.201405353","article-title":"Targeting Human C-Type Lectin-like Molecule-1 (CLL1) with a Bispecific Antibody for Immunotherapy of Acute Myeloid Leukemia","volume":"53","author":"Lu","year":"2014","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Van Loo, P.F., Doornbos, R., Dolstra, H., Shamsili, S., and Bakker, L. (2015). Preclinical Evaluation of MCLA117, a CLEC12AxCD3 Bispecific Antibody Efficiently Targeting a Novel Leukemic Stem Cell Associated Antigen in AML. Blood, 126.","DOI":"10.1182\/blood.V126.23.325.325"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.ymthe.2017.05.024","article-title":"Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1","volume":"25","author":"Tashiro","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Laborda, E., Mazagova, M., Shao, S., Wang, X., Quirino, H., Woods, A.K., Hampton, E.N., Rodgers, D.T., Kim, C.H., and Schultz, P.G. (2017). Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18112259"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Kenderian, S.S., Ruella, M., Shestova, O., Klichinsky, M., Kim, M.Y., Soderquist, C., Bagg, A., Singh, R., Richardson, C., and Young, R.M. (2016). Leukemia Stem Cells Are Characterized By CLEC12A Expression and Chemotherapy Refractoriness That Can be Overcome By Targeting with Chimeric Antigen Receptor T Cells. Blood, 128.","DOI":"10.1182\/blood.V128.22.766.766"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Wang, J., Chen, S., Xiao, W., Li, W., Wang, L., Yang, S., Wang, W., Xu, L., Liao, S., and Liu, W. (2018). CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia. J. Hematol. Oncol., 11.","DOI":"10.1186\/s13045-017-0553-5"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"De Togni, E., Kim, M.Y., Cooper, M.L., Ritchey, J., O\u2019Neal, J., Niswonger, J., and DiPersio, J.F. (2018). Chimeric Antigen Receptor T Cells Specific for CLL-1 for Treatment of Acute Myeloid Leukemia. Blood, 132.","DOI":"10.1182\/blood-2018-99-113438"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Arvindam, U.S., Van Hauten, P., Hallstrom, C., Vallera, D.A., Dolstra, H., Miller, J.S., and Felices, M. (2018). CD16-IL15-CLEC12A Trispecific Killer Engager (TriKE) Drives NK Cell Expansion, Activation, and Antigen Specific Killing of Cancer Stem Cells in Acute Myeloid Leukemia. Blood, 132.","DOI":"10.1182\/blood-2018-99-117150"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Gao, X., Lin, J., Gao, L., Deng, A., Lu, X., Li, Y., Wang, L., and Yu, L. (2015). High Expression of c-kit mRNA Predicts Unfavorable Outcome in Adult Patients with t(8;21) Acute Myeloid Leukemia. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0124241"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1038\/s41375-020-0818-9","article-title":"Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells","volume":"34","author":"Myburgh","year":"2020","journal-title":"Leukemia"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"7358","DOI":"10.4049\/jimmunol.180.11.7358","article-title":"Human Flt3 Is Expressed at the Hematopoietic Stem Cell and the Granulocyte\/Macrophage Progenitor Stages to Maintain Cell Survival","volume":"180","author":"Kikushige","year":"2008","journal-title":"J. Immunol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nrc1169","article-title":"The role of FLT3 in haematopoietic malignancies","volume":"3","author":"Stirewalt","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): A multicentre, randomised, controlled, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/s41375-018-0009-0","article-title":"CAR T-cells targeting FLT3 have potent activity against FLT3\u2212ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib","volume":"32","author":"Jetani","year":"2018","journal-title":"Leukemia"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Seitz, C.M., Kieble, C.V., Illi, C.C., Reiter, C.S., Grote, M.S., Mittelstaet, J., Lock, M.D., Kaiser, A., Schleicher, S., and Handgretinger, R. (2018). Combinatorial Targeting of Multiple Shared Antigens By Adapter-CAR-T Cells (aCAR-Ts) Allows Target Cell Discrimination and Specific Lysis Based on Differential Expression Profiles. Blood, 132.","DOI":"10.1182\/blood-2018-99-115630"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood.V128.22.763.763","article-title":"Phase IB\/II Study of Nivolumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML)","volume":"128","author":"Daver","year":"2016","journal-title":"Blood"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Daver, N.G., Garcia-Manero, G., Basu, S., Cortes, J.E., Ravandi, F., Kadia, T.M., Konopleva, M.Y., Jabbour, E.J., Dinardo, C.D., and Assi, R. (2018). Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed\/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study. Blood, 132.","DOI":"10.1182\/blood-2018-99-120157"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.1016\/S2352-3026(19)30114-0","article-title":"Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: A single-arm, phase 2 study","volume":"6","author":"Ravandi","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Lindblad, E.K., Thompson, J., Gui, G., Valdez, J., Worthy, T., Tekleab, H., Hughes, T., Goswami, M., Oetjen, K., and Kim, N.-Y. (2018). Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia. Blood, 132.","DOI":"10.1182\/blood-2018-99-115097"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for Patients with Relapse after Allogeneic Transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/blood-2008-07-168468","article-title":"CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation","volume":"113","author":"Bashey","year":"2009","journal-title":"Blood"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1158\/1078-0432.CCR-17-3763","article-title":"A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure","volume":"24","author":"Zeidan","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Borate, U., Esteve, J., Porkka, K., Knapper, S., Vey, N., Scholl, S., Garcia-Manero, G., Wermke, M., Janssen, J., and Traer, E. (2019). Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). Blood, 134.","DOI":"10.1182\/blood-2019-128178"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/mt.2013.154","article-title":"Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia","volume":"21","author":"Ritchie","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/mt.2014.164","article-title":"Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient with Relapsed and Refractory Acute Myeloid Leukemia","volume":"23","author":"Wang","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_125","unstructured":"Tang, X., Yang, L., Li, Z., Nalin, A.P., Dai, H., Xu, T., Yin, J., You, F., Zhu, M., and Shen, W. (2018). First-in-man clinical trial of CAR NK-92 cells: Safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am. J. Cancer Res., 8."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Suh, H.C., Pohl, K.A., Termini, C., Kan, J., Timmerman, J.M., Slamon, D.J., and Chute, J.P. (2018). Bioengineered Autologous Dendritic Cells Enhance CAR T Cell Cytotoxicity By Providing Cytokine Stimulation and Intratumoral Dendritic Cells. Blood, 132.","DOI":"10.1182\/blood-2018-99-115296"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Liu, F., Cao, Y., Pinz, K., Ma, Y., Wada, M., Chen, K., Ma, G., Shen, J., Tse, C.O., and Su, Y. (2018). First-in-Human CLL1-CD33 Compound CAR T Cell Therapy Induces Complete Remission in Patients with Refractory Acute Myeloid Leukemia: Update on Phase 1 Clinical Trial. Blood, 132.","DOI":"10.1182\/blood-2018-99-110579"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Sallman, D., Kerre, T., Poire, X., Havelange, V., Lewalle, P., Davila, M.L., Wang, E.S., Dekker, D., Snykers, S., and Sotiropoulou, P.A. (2018). Remissions in Relapse\/Refractory Acute Myeloid Leukemia Patients Following Treatment with NKG2D CAR-T Therapy without a Prior Preconditioning Chemotherapy. Blood, 132.","DOI":"10.1182\/blood-2018-99-111326"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2017-06-741058","article-title":"Redirecting T cells to hematological malignancies with bispecific antibodies","volume":"131","author":"Velasquez","year":"2018","journal-title":"Blood"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Ravandi, F., Stein, A.S., Kantarjian, H.M., Walter, P.M.R.B., Paschka, P., Jongen-Lavrencic, M., Ossenkoppele, G.J., Yang, Z., Mehta, B., and Subklewe, M. (2018). A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE\u00ae) Antibody Construct, in Relapsed\/Refractory Acute Myeloid Leukemia (R\/R AML). Blood, 132.","DOI":"10.1182\/blood-2018-99-109762"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Westervelt, P., Roboz, G.J., Cortes, J.E., Kantarjian, H.M., Lee, S., Rettig, M.P., Han, T.H., Guenot, J., Feldman, E.J., and DiPersio, J.F. (2018). Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2x2) CD33\/CD3 T-Cell Engager, in Patients with Relapsed\/Refractory Acute Myeloid Leukemia (AML). Blood, 132.","DOI":"10.1182\/blood-2018-99-111529"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Ravandi, F., Bashey, A., Foran, J.M., Stock, W., Mawad, R., Blum, W., Saville, M.W., Johnson, B.C.M., Vanasse, K.G.J., and Ly, T. (2018). Complete Responses in Relapsed\/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study. Blood, 132.","DOI":"10.1182\/blood-2018-99-119786"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Uy, G.L., Rettig, M.P., Vey, N., Godwin, J., Foster, M.C., Rizzieri, D.A., Arellano, M.L., Topp, M.S., Huls, G., and Jongen-Lavrencic, M. (2018). Phase 1 Cohort Expansion of Flotetuzumab, a CD123\u00d7CD3 Bispecific Dart\u00ae Protein in Patients with Relapsed\/Refractory Acute Myeloid Leukemia (AML). Blood, 132.","DOI":"10.1182\/blood-2018-99-117085"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Wei, A.H., Fong, C.Y., Montesinos, P., Calbacho, M., Gil, J.S., De Oteyza, J.P., Rowe, J.M., Wolach, O., Ofran, Y., and Moshe, Y. (2019). A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART\u00ae Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood, 134.","DOI":"10.1182\/blood-2019-125966"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1200\/JCO.2015.64.0060","article-title":"Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial","volume":"34","author":"Amadori","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/annonc\/mdy551","article-title":"Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors","volume":"30","author":"Heinhuis","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Dagoglu, N., Karaman, S., Caglar, H.B., and Oral, E.N. (2019). Abscopal Effect of Radiotherapy in the Immunotherapy Era: Systematic Review of Reported Cases. Cureus, 11.","DOI":"10.7759\/cureus.4103"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/4\/1944\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:24:54Z","timestamp":1760160294000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/4\/1944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,16]]},"references-count":137,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["ijms22041944"],"URL":"https:\/\/doi.org\/10.3390\/ijms22041944","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,16]]}}}